Helsinn Group, a fully integrated, global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, has closed a financing agreement with Oberland Capital Management. The funding will allow the company to expand the portfolio of late- and commercial-stage oncology and rare disease products.
The Lugano-based group is a fully integrated global biopharma group with a strong focus on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.
Oberland Capital is a private investment firm formed in 2013 with assets under management in excess of $3 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners.
Bär & Karrer advised the Helsinn Group on its financing agreement acting as Swiss legal advisor in this transaction. The team was led by partner Paolo Bottini (corporate / m&a and tax, pictured left) and associate Andrea Ziswiler (corporate / m&a and banking, insurance & finance, pictured right), as well as Susanne Schreiber, Elena Kumashova, Michel Morelato and Aron Liechti (all tax).